GS70 Analyst Ratings
Moderate Buy
1 Buy
2 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
GS70 Stock 12 Month Forecast
Average Price Target
€55.57
▲(28.04% Upside)
| Highest Price Target€62.77 | Average Price Target€55.57 | Lowest Price Target€50.13 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Jefferies
€60.44→€50.13
Hold
15.51%
Upside
Downgraded
10/28/26
TD Cowen
€62.77
Hold
44.64%
Upside
Reiterated
08/03/26
Argus Research
―
Buy
―
Reiterated
06/08/26
We expect this trend to continue over the next year. We see value in GSK shares, which are trading at below-industry-average P/E multiples. The shares also offer an attractive dividend, with a yield of about 3.8%. The shares are listed on the New York Stock Exchange in the form of American Depositary Receipts (ADRs), each of which represents two ordinary shares. Our revised target price of $60 implies a projected 2026 P/E of 12 — and a total potential return, including the dividend, of about 22% from current levels. RECENT DEVELOPMENTS GSK shares have underperformed over the past quarter, falling 7%, compared to a gain of 1% for the sector ETF IYH and growth of 11% for the S&P 500.
Barclays
―
Sell
―
Downgraded
01/06/26
Unknown Analyst
HSBCNot Ranked
HSBC
€14.34→€17.93
Sell
-58.70%
Downside
Reiterated
12/02/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Jefferies
€60.44→€50.13
Hold
15.51%
Upside
Downgraded
10/28/26
TD Cowen
€62.77
Hold
44.64%
Upside
Reiterated
08/03/26
Argus Research
―
Buy
―
Reiterated
06/08/26
We expect this trend to continue over the next year. We see value in GSK shares, which are trading at below-industry-average P/E multiples. The shares also offer an attractive dividend, with a yield of about 3.8%. The shares are listed on the New York Stock Exchange in the form of American Depositary Receipts (ADRs), each of which represents two ordinary shares. Our revised target price of $60 implies a projected 2026 P/E of 12 — and a total potential return, including the dividend, of about 22% from current levels. RECENT DEVELOPMENTS GSK shares have underperformed over the past quarter, falling 7%, compared to a gain of 1% for the sector ETF IYH and growth of 11% for the S&P 500.
Barclays
―
Sell
―
Downgraded
01/06/26
Unknown Analyst
HSBCNot Ranked
HSBC
€14.34→€17.93
Sell
-58.70%
Downside
Reiterated
12/02/25
Best Analysts Covering GlaxoSmithKline
3 Months
Success Rate
2/2 ratings generated profit
Average Return
+6.95%
Copying xAi Drug Manufacturers - General's trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +6.95% per trade.
1 Year
Success Rate
1/2 ratings generated profit
Average Return
+5.90%
Copying xAi Drug Manufacturers - General's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +5.90% per trade.
2 Years
Success Rate
1/2 ratings generated profit
Average Return
+21.55%
Copying Jasper Hellweg's trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +21.55% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
GS70 Analyst Recommendation Trends
Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
0
0
0
0
0
Buy
2
2
1
1
1
Hold
2
2
2
1
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
4
4
3
2
3
Each month's total comprises the sum of three months' worth of ratings.
GS70 Financial Forecast
GS70 Stock Forecast FAQ
What is DE:GS70’s average 12-month price target, according to analysts?
Based on analyst ratings, GlaxoSmithKline’s 12-month average price target is 55.57.
What is DE:GS70’s upside potential, based on the analysts’ average price target?
GlaxoSmithKline has 28.04% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is GlaxoSmithKline a Buy, Sell or Hold?
GlaxoSmithKline has a consensus rating of Moderate Buy, which is based on 1 buy ratings, 2 hold ratings and 0 sell ratings.
What is GlaxoSmithKline’s share price target?
The average share price target for GlaxoSmithKline is 55.57. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €62.77 ,and the lowest forecast is €50.13. The average share price target represents 28.04% Increase from the current price of €43.4.
The highest analyst share price target is €62.77 ,and the lowest forecast is €50.13. The average share price target represents 28.04% Increase from the current price of €43.4.
What do analysts say about GlaxoSmithKline?
GlaxoSmithKline’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 3 Wall Streets Analysts.
How can I buy shares of GlaxoSmithKline?
To buy shares of DE:GS70, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.